Efficacy of an inactivated vaccine for equine herpesvirus type 1 in a novel hamster model

Intervirology

Volumn 43, Issue 1, 2000, Pages 27-35

  Skinner, G R B ^a   Davies, Judith A ^b  

^a UNIVERSITY OF BIRMINGHAM   (United Kingdom)

^b Vaccine Research Trust   (United Kingdom)

Author keywords

Animal model; Equine herpesvirus; Inactivated vaccine

Indexed keywords

HERPES VACCINE; VIRUS ANTIBODY; VIRUS DNA;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANTIBODY RESPONSE; ARTICLE; CONTROLLED STUDY; DRUG EFFICACY; EQUINE HERPES VIRUS; HAMSTER; NONHUMAN; PRIORITY JOURNAL; VACCINATION; VIRUS INFECTION;

ANIMALIA; CRICETINAE; EQUIDAE; EQUINE HERPESVIRUS 1; HERPESVIRIDAE; ORYCTOLAGUS CUNICULUS; RODENTIA;

EID: 0034029014     PISSN: 03005526     EISSN: None     Source Type: Journal    
DOI: 10.1159/000025020     Document Type: Article

References (44)

1. O'Callaghan DJ, Gentry GA, Randall CC: The equine herpesviruses; in Roizman B (ed): The Herpesviruses. New York, Plenum, 1983, vol 2, pp 215-318.
2. Comment. Vet Rec 1984;114:15.
3. Thomson GR: The role of equid herpesvirus 1 in acute respiratory disease of horses and the use of inactivated antigens to immunise against the infection; PhD thesis. University of London, 1978.
4. Doll ER, Bryans JT: A planned infection programme for immunising mares against viral rhinopneumonitis. Cornell Vet 1963;53:249-262.
5. Mumford JA: Research and development of vaccines against EHV1 abortion - progress and problems. The Thoroughbred Breeder, May, 1989.
6. Jackson TA, Osburn BI, Cordy DR, Kendrick JW: Equine herpesvirus 1 infection of horses: Studies on the experimentally induced neurologic disease. Am J Vet Res 1977;38:709-718.
7. Bryans JT: Serologic responses of pregnant thoroughbred mares to vaccination with an inactivated equine herpesvirus 1 vaccine. Am J Vet Res 1980;41:1743-1746.
8. Bryans JT: Immunisation of pregnant mares with an inactivated equine herpesvirus 1 vaccine; in Bryans JT, Gerbar H (eds): Proc 4th Int Conf Equine Infect Dis, Lyon, 1976. Princetown. Veterinary Publications Inc. 1978, pp 83-92.
9. Bryans JT, Allen GP: Application of a chemically inactivated, adjuvanted vaccine to control abortigenic infection of mares by equine herpesvirus 1; in Bonneau M. Hennessen W (eds): Dev Biol Stand. Basel, Karger, 1982, vol 52. pp 493-498.
10. Burrows R, Goodridge D, Denver MS: Trials of inactivated equid herpesvirus 1 vaccine: Challenge with a subtype 1 virus. Vet Rec 1984;114: 369-374.
11. Gleesan LJ, Coggins L: Response of pregnant mares to equine herpesvirus 1 (EHV 1). Cornell Vet 1980;70:391-400.
12. Ellis JA, Bogdan JR, Kanara EW, Morley PS, Haines DM: Cellular and antibody responses to equine herpesviruses 1 and 4 following vaccination of horses with modified-live and inactivated viruses. J Am Vet Med Assoc 1995:206: 823-832.
13. Dolby CA, Hannant D, Mumford JA: Response of ponies to adjuvanted EHV-1 whole virus vaccine and challenge with virus of the homologous strain. Br Vet J 1995;151:27-37.
14. Herrman R: Cavallon® IR - a new combination vaccine against equine influenza and rhinopneumonitis. Prakt Tierarzt 1995;76:18.
15. Colls CF 3rd, Tarbet EB, Grafton WD, Jennings SR, O'Callaghan DJ: Equine herpesvirusI strain KyA, a candidate vaccine strain, reduces viral liters in mice challenged with a pathogenic strain, RacL. Virus Res 1996;43: 111-124.
16. Smith PM, Zhang YF, Jennings SR, O'Callaghan DJ: Characterization of the cytolytic T-lymphocyte response to a candidate vaccine strain of equine herpesvirus 1 in CBA mice. J Virol 1998;72:5366-5372.
17. Neubauer A, Beer M, Brandmuller C, Kaaden OR, Osterreider N: Equine herpesvirus 1 mutants devoid of glycoprotein B or M are apathogenic for mice but induce protection against challenge infection. Virology 1997;239:36-45.
18. Marshall KR, Sun Y, Brown SM, Field HJ: An equine herpesvirus-1 gene 71 deletant is attenuated and elicits a protective immune response in mice. Virology 1997;231:20-27.
19. Matsumura T, O'Callaghan DJ, Kondo T, Kamada M: Lack of virulence of the murine fibroblast adapted strain, Kentucky A (KyA), of equine herpesvirus type 1 (EHV-1) in young horses. Vet Microbiol 1996;48:353-365.
20. Ellis JA, Steeves E, Wright AK, Bogdan JR, Davis WC, Kanara EW, Haines DM: Cellmediated cytolysis of equine herpesvirus-infected cells by leukocytes from young vaccinated horses. Vet Immunol Immunopathol 1997;57:201-214.
21. Schrag D, Floss G, Koene M: Efficacy and tolerability of early intranasal immunizations of foals with Prevaccinol®. Prakt Tierarzt 1997;78:108-115.
22. Osterrieder N, Wagner R, Brandmuller C, Schmidt P, Wolf H, Kaaden OR: Protection against EHV-1 challenge infection in the murine model after vaccination with various formulations of recombinant glycoprotein gP14 (gB). Virology 1995;208:500-510.
23. Stokes A, Alber DG, Greensill J, Amellal B, Carvalho R, Taylor LA, Doel TR, Killington RA, Halliburton IW, Meredith DM: The expression of the proteins of equine herpesvirus 1 which share homology with herpes simplex virus 1 glycoproteins H and L. Virus Res 1996; 40:91-107.
24. k) mice against virus challenge. Virus Res 1996;44:97-109.
25. k) murine model. Virus Res 1997; 50:159-173.
26. Kukreja A, Love DN, Whalley JM, Field HJ: Study of the protective immunity of co-expressed glycoprotein H and J of equine herpesvirus-1 in a murine intranasal infection model. Vet Microbiol 1998;60:1-11.
27. McPherson I, Stoker M: Polyoma transformation of hamster cell clones-an investigation of the genetic factors affecting cell competence. Virology 1962;16:147-151.
28. Russell WC: A sensitive and precise plaque assay for herpesvirus. Nature 1962;195:1028-1029.
29. Holmes PJ, Hallworth JA. Stocker DI, Skinner GRB: Augmentation of the neutralisation test for type 1 HSV: Evidence of high representation of neutralising antibody in the adult community. Med Microbiol Immunol (Berl) 1985; 174:167-175.
30. Skinner GRB, Davies J, Billstrom MA, Buchan A: In vivo model for evaluation of species-specific virus vaccines. Vaccine 1992;10:847-851.
31. Skinner GRB, Durham J, Davies J, Buchan A: Efficacy of inactivated vaccine against equine abortion virus in a rodent model. 11th International Symposium of the World Association of Veterinary Microbiologists, Immunologists and Specialists in Infectious Diseases. Perugia, 1989.
32. Billstrom MA: A study of the development of vaccines against cytomegalovirus disease: PhD thesis. University of Birmingham, 1991.
33. Billstrom MA, Davies JA, Skinner GRB, Buchan A: Development of subunit preparations of cytomegalovirus antigen by aqueous extraction for immunisation against cytomegalovirus infection. Intcrvirology 1993;36:20-31.
34. Allen G, Yeargean M, Costa LR, Cross R: Major histocompatibility complex class 1-restricted cytotoxic T-lymphocyte responses in horses infected with equine herpesvirus 1. J Virol 1995;69:606-612.
35. Charan S, Palmer K, Chester P, Mire Sluis AR, Meager A, Edington N: Transforming growth factor-beta induced by live or ultraviolet-inactivated equid herpesvirus type-1 mediates immunosuppression in the horse. Immunology 1997;90:586-591.
36. Stokes A, Allen GP, Pullen LA, Murray PK: A hamster model of equine herpesvirus type 1 (EHV-1) infection; passive protection by monoclonal antibodies to EHV-1 glycoproteins 13, 14, and 17/18. J Gen Virol 1989;70:1173-1183.
37. Tewari D, Whalley JM, Love DN, Field HJ: Characterization of immune responses to baculovirus-expressed equine herpcsvirus type 1 glycoproteins D and H in a murine model. J Gen Virol 1994;75:1735-1741.
38. D) mice. Res Vet Sci 1995;59: 205-213.
39. Mertz GH, Ashley R, Burk RL, Benedetti J, Critchlow C, Jones CC, Corey L: Double-blind, placebo-controlled trial of HSV type 2 glycoprotein vaccine in persons at high risk for genital herpes infections. J Infect Dis 1990;161: 653-660.
40. Onions D: Equine herpesviruses: New approaches to an old problem. Equine Vet J 1991; 23:6-7.
41. -)BHK. 14th International Symposium of the World Association of Veterinary Microbiologists, Immunologists and Specialists in Infectious Diseases. Edinbourgh, UK, 1996.
42. Skinner GRB, Williams DR, Moles AW, Sargent A: Pre-pubertal vaccination of mice against experimental infection of the genital tract with type 2 herpes simplex virus. Arch Virol 1980;47:111-112.
43. Skinner GRB, Buchan A, Durham J, Cowan M, Davies J, Brookes K, Castrucci R: Role of bovine mammilitis virus towards preparation of an alternative vaccine against herpes simplex virus infections of human subjects. Vaccine 1987;5:55-59.
44. Ahmad A: Vaccine against staphylococcal disease by sequential release of antigens from solvent treated bacterial cells; MSc thesis, University of Birmingham, 1994.